Targeted delivery of doxorubicin to breast cancer cells by aptamer functionalized DOTAP/DOPE liposomes

Song,Xingli; Ren,Yi; Zhang,Jing; Wang,Gang; Han,Xuedong; Zheng,Wei; Zhen,Linlin

doi:10.3892/or.2015.4136

Targeted delivery of doxorubicin to breast cancer cells by aptamer functionalized DOTAP/DOPE liposomes

Authors:
- Xingli Song
- Yi Ren
- Jing Zhang
- Gang Wang
- Xuedong Han
- Wei Zheng
- Linlin Zhen
View Affiliations

Affiliations: Department of Breast Surgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, P.R. China, Department of Breast and Thyroid Surgery, Huai'an First People's Hospital, Nanjing Medical University, Huai'an, Jiangsu, P.R. China, Department of Breast Surgery, Xuzhou Tumor Hospital, Xuzhou, Jiangsu, P.R. China, Department of General Surgery, Beijing Aerospace General Hospital, Beijing, P.R. China
Published online on: July 17, 2015 https://doi.org/10.3892/or.2015.4136
Pages: 1953-1960

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Doxorubicin is used to treat numerous types of tumors including breast cancer, yet dose-associated toxicities limit its clinical application. Here, we demonstrated a novel strategy by which to deliver doxorubicin to breast cancer cells by conjugating cancer cell-specific single-strand DNA aptamers with doxorubicin-encapsulated DOTAP:DOPE nanoparticles (NPs). We utilizing a whole-cell-SELEX strategy, and 4T1 cells with high invasive and metastatic potential were used as target cells, while non-invasive and non-metastatic 67NR cells were used as subtractive cells. Ten potential aptamers were generated after multi-pool selection. Studies on the selected aptamers revealed that SRZ1 had the highest and specific binding affinity to 4T1 cells. Then we developed SRZ1 aptamer-carried DOTAP:DOPE-DOX NPs. In vitro uptake results which were conducted by FACS indicated that the aptamer significantly promoted the uptake efficiency of DOTAP:DOPE-DOX NPs by 4T1 cells. ATPlite assay was performed to test 4T1, 67NR and NMuMG cell viability after treatment with free doxorubicin, DOTAP:DOPE-DOX particles and aptamer‑loaded DOTAP:DOPE-DOX particles. As expected, the aptamers effectively enhanced accumulation of doxorubicin in the 4T1 tumor tissues as determined by in vivo mouse body images and biodistribution analysis. Consistent with the in vitro findings, aptamer-conjugated doxorubicin-loaded DOTAP:DOPE particles markedly suppressed tumor growth and significantly increased the survival rate of 4T1 tumor-bearing mice. These studies demonstrated that aptamer SRZ1 could be a promising molecule for chemotherapeutic drug targeting deliver.

View Figures

View References

1	Wang B, He M and Wang L, Engelgau MM, Zhao W and Wang L: Breast cancer screening among adult women in China, 2010. Prev Chronic Dis. 10:E1832013. View Article : Google Scholar : PubMed/NCBI
2	MacDonald V: Chemotherapy: managing side effects and safe handling. Can Vet J. 50:665–668. 2009.PubMed/NCBI
3	Lin X, Gao R, Zhang Y, Qi N, Zhang Y, Zhang K, He H and Tang X: Lipid nanoparticles for chemotherapeutic applications: strategies to improve anticancer efficacy. Expert Opin Drug Deliv. 9:767–781. 2012. View Article : Google Scholar : PubMed/NCBI
4	De Jong WH and Borm PJ: Drug delivery and nanoparticles: applications and hazards. Int J Nanomed. 3:133–149. 2008. View Article : Google Scholar
5	Shohdy KS and Alfaar AS: Nanoparticles targeting mechanisms in cancer therapy: current limitations and emerging solutions. Ther Deliv. 4:1197–1209. 2013. View Article : Google Scholar : PubMed/NCBI
6	Bastakoti BP, Torad NL and Yamauchi Y: Polymeric micelle assembly for the direct synthesis of platinum-decorated mesoporous TiO₂ toward highly selective sensing of acetaldehyde. ACS Appl Mater Interfaces. 6:854–860. 2014. View Article : Google Scholar : PubMed/NCBI
7	Quan L, Zhang Y, Crielaard BJ, Dusad A, Lele SM, Rijcken CJ, Metselaar JM, Kostková H, Etrych T, Ulbrich K, et al: Nano-medicines for inflammatory arthritis: head-to-head comparison of glucocorticoid-containing polymers, micelles, and liposomes. ACS Nano. 8:458–466. 2014. View Article : Google Scholar :
8	Chang DK, Li PC, Lu RM, Jane WN and Wu HC: Peptide-mediated liposomal doxorubicin enhances drug delivery efficiency and therapeutic efficacy in animal models. PLoS One. 8:e832392013. View Article : Google Scholar
9	Wang Q, Zhuang X, Mu J, Deng ZB, Jiang H, Zhang L, Xiang X, Wang B, Yan J, Miller D, et al: Delivery of therapeutic agents by nanoparticles made of grapefruit-derived lipids. Nat Commun. 4:18672013. View Article : Google Scholar : PubMed/NCBI
10	Park K: Lessons learned from thermosensitive liposomes for improved chemotherapy. J Control Release. 174:2192014. View Article : Google Scholar : PubMed/NCBI
11	Sabnis N and Lacko AG: Drug delivery via lipoprotein-based carriers: answering the challenges in systemic therapeutics. Ther Deliv. 3:599–608. 2012. View Article : Google Scholar : PubMed/NCBI
12	Lacko AG, Nair M, Prokai L and McConathy WJ: Prospects and challenges of the development of lipoprotein-based formulations for anti-cancer drugs. Expert Opin Drug Deliv. 4:665–675. 2007. View Article : Google Scholar : PubMed/NCBI
13	Lassalle HP, Marchal S, Guillemin F, Reinhard A and Bezdetnaya L: Aptamers as remarkable diagnostic and therapeutic agents in cancer treatment. Curr Drug Metab. 13:1130–1144. 2012. View Article : Google Scholar : PubMed/NCBI
14	Bunka DH, Platonova O and Stockley PG: Development of aptamer therapeutics. Curr Opin Pharmacol. 10:557–562. 2010. View Article : Google Scholar : PubMed/NCBI
15	Shi H, Cui W, He X, Guo Q, Wang K, Ye X and Tang J: Whole cell-SELEX aptamers for highly specific fluorescence molecular imaging of carcinomas in vivo. PLoS One. 8:e704762013. View Article : Google Scholar : PubMed/NCBI
16	Meyer S, Maufort JP, Nie J, Stewart R, McIntosh BE, Conti LR, Ahmad KM, Soh HT and Thomson JA: Development of an efficient targeted cell-SELEX procedure for DNA aptamer reagents. PLoS One. 8:e717982013. View Article : Google Scholar : PubMed/NCBI
17	Dassie JP and Giangrande PH: Current progress on aptamer-targeted oligonucleotide therapeutics. Ther Deliv. 4:1527–1546. 2013. View Article : Google Scholar : PubMed/NCBI
18	Subramanian N, Raghunathan V, Kanwar JR, Kanwar RK, Elchuri SV, Khetan V and Krishnakumar S: Target-specific delivery of doxorubicin to retinoblastoma using epithelial cell adhesion molecule aptamer. Mol Vis. 18:2783–2795. 2012.PubMed/NCBI
19	Tacar O, Sriamornsak P and Dass CR: Doxorubicin: an update on anticancer molecular action, toxicity and novel drug delivery systems. J Pharm Pharmacol. 65:157–170. 2013. View Article : Google Scholar : PubMed/NCBI
20	Carvalho C, Santos RX, Cardoso S, Correia S, Oliveira PJ, Santos MS and Moreira PI: Doxorubicin: the good, the bad and the ugly effect. Curr Med Chem. 16:3267–3285. 2009. View Article : Google Scholar : PubMed/NCBI
21	Speelmans G, Staffhorst RW, De Kruijff B and De Wolf FA: Transport studies of doxorubicin in model membranes indicate a difference in passive diffusion across and binding at the outer and inner leaflets of the plasma membrane. Biochemistry. 33:13761–13768. 1994. View Article : Google Scholar : PubMed/NCBI
22	Kamba SA, Ismail M, Hussein-Al-Ali SH, Ibrahim TA and Zakaria ZA: In vitro delivery and controlled release of doxorubicin for targeting osteosarcoma bone cancer. Molecules. 18:10580–10598. 2013. View Article : Google Scholar : PubMed/NCBI
23	Shaikh IM, Tan KB, Chaudhury A, Liu Y, Tan BJ, Tan BM and Chiu GN: Liposome co-encapsulation of synergistic combination of irinotecan and doxorubicin for the treatment of intraperitoneally grown ovarian tumor xenograft. J Control Release. 172:852–861. 2013. View Article : Google Scholar
24	Zhaorigetu S, Rodriguez-Aguayo C, Sood AK, Lopez-Berestein G and Walton BL: Delivery of negatively charged liposomes into the atherosclerotic plaque of apolipoprotein E-deficient mouse aortic tissue. J Liposome Res. 24:182–190. 2014. View Article : Google Scholar : PubMed/NCBI
25	Alavi SE, Esfahani MK, Alavi F, Movahedi F and Akbarzadeh A: Drug delivery of hydroxyurea to breast cancer using liposomes. Indian J Clin Biochem. 28:299–302. 2013. View Article : Google Scholar :
26	Remaut K, Lucas B, Braeckmans K, Sanders NN, Demeester J and De Smedt SC: Delivery of phosphodiester oligonucleotides: can DOTAP/DOPE liposomes do the trick? Biochemistry. 45:1755–1764. 2006. View Article : Google Scholar : PubMed/NCBI
27	Ciani L, Casini A, Gabbiani C, Ristori S, Messori L and Martini G: DOTAP/DOPE and DC- Chol/DOPE lipoplexes for gene delivery studied by circular dichroism and other biophysical techniques. Biophys Chem. 127:213–220. 2007. View Article : Google Scholar : PubMed/NCBI